US5173302A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hydrophilic pressure sensitive adhesive for topical administration of hydrophobic drugs
Assignee: Ludlow Corp
•
Filing: 1990-09-28
•
Granted: 1992-12-22
•
Expires: 2010-09-28
Abstract
Abstract Novel hydrogel formulations useful as adhesive reservoirs for topical or transdermal drugs employ as the polymer base a crosslinked polymer or copolymer of 2-acrylamido-2-methylpropanesulfonic acid or a salt thereof. The gels are prepared from polymerizable compositions comprising: 20%-50% of a monofunctional monomer component, at least 75% of said component comprising 2-acrylamido-2-methylpropane sulfonic acid or a salt thereof, the balance being selected from the group consisting of acrylic acid, water soluble acrylic functional monomers and vinyl pyrrolidone; 30%-50% of a glycol component selected from the group consisting of compounds of the formula HO-(C2H4O)n-H, HO-(C3H6O)m-H and mixtures thereof, where n is in the range of about 4 to about 16 and m is 1-4; between about 0.02% and about 0.20% of a crosslinking monomer; an amount of a free radical polymerization initiator effective for initiating polymerization of said monofunctional monomer and crosslinking monomer components; and a therapeutically effective amount of a topically or transdermally deliverable drug, at least about 60% of said drug being dissolved in the formulation.
Inventors
- 👤 Carolann M. Holmblad
- 👤 Joan M. Bergstrom
- 👤 Terese A. Bartlett
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 05:33
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7038; A61K9/7046; A61K9/7053; A61K9/7061; A61L; A61L15/00; A61L15/16; A61L15/42; A61L15/58
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
138 words
A polymerizable composition comprising: 20%-50% of a monofunctional monomer component, at least 75% of said component comprising 2-acrylamido-2-methylpropane sulfonic acid or a salt thereof, the balance being selected from the group consisting of acrylic acid, water soluble acrylic functional monomers and vinyl pyrrollidone; 30%-50% of a hymectant selected from the group consisting of compounds of the formula HO--(C.sub.2 H.sub.4 O).sub.n --H, HO--(C.sub.3 H.sub.6 O).sub.m --H and mixtures thereof, where n is in the range of about 4 to about 16 and m is 1-4; between about 0.02% and about 0.20% of a crosslinking monomer; an amount of a free radical polymerization initiator effective for initiating polymerization of said monofunctional monomer and crosslinking monomer components; and a therapeutically effective amount of a topically or transdermally deliverable drug, at least about 60% of said drug being dissolved in the formulation.
Claim 2
Dependent Claim
138 words
A polymerizable composition comprising: 20%-50% of a monofunctional monomer component, at least 75% of said component comprising 2-acrylamido-2-methylpropane sulfonic acid or a salt thereof, the balance being selected from the group consisting of acrylic acid, water soluble acrylic functional monomers and vinyl pyrrollidone; 30%-50% of a hymectant selected from the group consisting of compounds of the formula HO--(C.sub.2 H.sub.4 O).sub.n --H, HO--(C.sub.3 H.sub.6 O).sub.m --H and mixtures thereof, where n is in the range of about 4 to about 16 and m is 1-4; between about 0.02% and about 0.20% of a crosslinking monomer; an amount of a free radical polymerization initiator effective for initiating polymerization of said monofunctional monomer and crosslinking monomer components; and a therapeutically effective amount of a topically or transdermally deliverable drug, at least about 60% of said drug being dissolved in the formulation.
Claim 3
Dependent Claim
13 words
A composition as in claim 1 wherein said drug is a hydrophobic drug.
Claim 4
Dependent Claim
13 words
A composition as in claim 2 wherein the hydrophobic drug is a corticosteroid.
Claim 5
Dependent Claim
33 words
A composition as in claim 3 wherein the hydrophobic drug is selected from the group consisting of hydrocortisone and its pharmaceutically acceptable esters, betamethasone and its pharmaceutically acceptable esters, fluocinoide and trimcinolone acetonide.
Claim 6
Dependent Claim
12 words
A composition as in claim 4 wherein the hydrophobic drug is hydrocortisone.
Claim 7
Dependent Claim
19 words
A composition as in claim 5 wherein the hydrocortisone is present at a level of about 0.5-1% by weight.
Claim 8
Dependent Claim
13 words
A composition as in claim 3 wherein the hydrophobic drug is hydrocortisone hemisuccinate.
Claim 9
Dependent Claim
20 words
A composition as in claim 7 wherein the hydrocortisone hemisuccinate is present at a level of about 0.5-3.0% by weight.
Claim 10
Dependent Claim
10 words
A composition as in claim 7 having a neutral pH.
Claim 11
Dependent Claim
15 words
A composition as in claim 1 wherein the drug is an analgesic, antiinfective or anesthetic.
Claim 12
Dependent Claim
23 words
A composition as in claim 1 wherein the monofunctional monomer component is present at a level of between about 25% and about 50%.
Claim 13
Dependent Claim
24 words
A composition as in claim 11 wherein the monofunctional monomer component includes acrylic acid in addition to said 2-acrylamido-2-methylpropane sulfonic acid or salt thereof.
Claim 14
Dependent Claim
22 words
A composition as in claim 12 wherein the acrylic acid comprises between about 6% and about 18% of said monofunctional monomer component.
Claim 15
Dependent Claim
13 words
A composition as in claim 1 wherein the humectant is polyethylene glycol 300.
Claim 16
Dependent Claim
23 words
A tacky, drug containing adhesive leaving substantially no residue when pulled from skin comprising a cured product of the formulation of claim 1.
Claim 17
Dependent Claim
16 words
An adhesive as in claim 15 wherein the drug is substantially dissolved in said cured formulation.
Claim 18
Dependent Claim
16 words
An adhesive as in claim 15 wherein the drug is a corticosteroid, antiinfective, analgesic or anesthetic.
Claim 19
Dependent Claim
28 words
An adhesive as in claim 17 wherein the drug is selected from hydrocortisone and its pharmaceutically acceptable esters, betamethasone and its pharmaceutically acceptable esters, fluocinoide and triaminicinolone acetonide.
Claim 20
Dependent Claim
15 words
An adhesive as in claim 18 wherein the drug is hydrocortisone or an ester thereof.
Claim 21
Dependent Claim
13 words
An adhesive as in claim 15 wherein the drug is a hydrophobic drug.
Claim 22
Dependent Claim
36 words
A therapeutic patch for topical or transdermal application of a drug having a laminate structure comprising a flexible top liner, a reinforced layer of an adhesive as in claim 15 and a peelable bottom release liner.
Claim 23
Dependent Claim
36 words
A patch as in claim 21 wherein the flexible top liner is a flexible polyether polyurethane sheet material, the adhesive is reinforced with a fabric material and the bottom release liner is a polyester sheet material.
Claim 24
Dependent Claim
16 words
A patch as in claim 22 wherein the reinforcing fabric is a spun bonded polyester fabric.
Claim 25
Dependent Claim
37 words
A patch as in claim 21 prepared by applying a polymerizable composition as in claim 1 to said bottom liner through said reinforcing fabric, photocuring the polymerizable composition and then covering the composition with the bottom liner.
References Cited (Backward Citations)
US2973300A
Cited
US3214338A
Cited
US3632740A
Cited
US3888995A
Cited
US3592930A
Cited
US3536809A
Cited
US3598122A
Cited
US3598123A
Cited
US3598122B1
Cited
US3734097A
Cited
US4017615A
Cited
US3731683A
Cited
US3742951A
Cited
US3742951B1
Cited
US3948254A
Cited
US3931087A
Cited
US3929741A
Cited
US4191743A
Cited
US4307717A
Cited
US4675009A
Cited
US4210633A
Cited
US4230105A
Cited
US4391278A
Cited
US4409206A
Cited
US4292301A
Cited
US4470962A
Cited
US4286592A
Cited
US4768523A
Cited
US4477325A
Cited
US4605548A
Cited
US4551490A
Cited
US4655768A
Cited
US4593053A
Cited
US4668506A
Cited
US4713244A
Cited
US4931279A
Cited
US4738257A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-12-22 | 1996-06-22 | 1996-12-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-12-22 | 2000-06-22 | 2000-12-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-12-22 | 2004-06-22 | 2004-12-22 | $7700.00 | Window Closed / Lapsed |